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INTRODUCTION
A telomere is a group of tandemly repeated DNA sequences
located at the ends of eukaryotic chromosomes (1). In humans,
telomeres are composed of 800-3,000 repeats of 5′ -TTA
GGG-3′ , constituting 5-15 kilobases in total (2, 3). Telom-
eres are thought to stabilize chromosomes and protect them
from end-to-end fusion or exonucleolytic degradation (4-7).
Telomeres cannot be replicated completely by DNA poly-
merases because the enzymes cannot continue copying to the
very ends of the DNA strands. Therefore, the telomere length
gradually decreases with successive cell divisions (and thus
with aging), resulting in chromosomal instability and genet-
ic changes that may lead to tumor development (5, 8, 9). A
reduction in telomere length has been reported in a subset
of tumors, including colorectal and renal cell carcinomas and
childhood leukemia (9-11). Telomerase is a ribonucleopro-
tein, the RNA component of which acts as a template for
the synthesis of the telomere sequence by reverse transcrip-
tion. Avoiding telomeric shortening by expressing telom-
erase may contribute to an immortality phenotype (4).
The variations in telomere length between individual col-
orectal carcinomas may represent the different stages of car-
cinogenesis and therefore, the biologic behavior of individual
tumors. It has been reported that telomere shortening fre-
quently occurs in both colorectal carcinomas and colonic
adenomas, but little telomerase activation has been noted in
colonic adenomas, whereas it is already strongly activated in
early colorectal carcinoma (9, 12).
In this study, we examined the telomere lengths in colorec-
tal carcinomas, matched adjacent normal colon tissues, and
polyps, with special reference to their clinical features and
histological findings. From the accumulated data, we deter-
mined whether the telomere length is predictive of the bio-
logic characteristics of human colorectal carcinomas.
MATERIALS AND METHODS
Materials
Twenty samples from invasive colorectal carcinomas, with
matched adjacent normal colorectal tissues, and twenty sam-
ples from colonic polyps, with adjancent normal colorectal
tissues, were studied. In each case, tumorous and normal
mucosa samples, at least 5 cm apart, were obtained from
Hyeong Rok Kim, Young Jin Kim, 
Hyun Jong Kim, Shin Kon Kim, 
Ji Hee Lee*
Department of Surgery, Chonnam National University
Medical School, and Research Institute* of Chonnam
National University Hospital, Gwangju, Korea 
Address for correspondence
Hyeong Rok Kim, M.D.
Division of Gastroenterologic Surgery, Department of
Surgery, Chonnam National University Medical School,
8 Hak-dong, Dong-gu, Gwangju 501-757, KOREA
Tel : +82.62-220-6457, Fax : +82.62-227-1635
E-mail : drkhr@chonnam.ac.kr
360
J Korean Med Sci 2002; 17: 360-5
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Telomere Length Changes in Colorectal Cancers and Polyps
Telomere shortening and telomerase activation occur frequently in cases of colo-
rectal carcinoma. In this study, we correlated the clinicopathological parameters
with the telomere length in colorectal carcinomas, colonic polyps, and normal colo-
nic tissues. We also investigated whether the telomere length changes reflect the
biologic behavior of tumors and different modes of tumor development. Telomere
length was determined by terminal restriction fragment Southern blot analysis in
20 invasive colorectal carcinomas and normal mucosa from the same patients.
We also examined 20 colonic polyps and associated normal mucosa. Telomere
shortening was detected in 16/20 (80%), and telomere elongation in 2/20 (10%)
cases of colorectal carcinoma, and no changes in 2 subjects. In the colonic polyp
patients, shortening was detected in 4/20 (20%), elongation in 6/20 (30%), and
no change in 10/20 (50%). The frequency of telomere shortening was significant-
ly different between colorectal carcinoma and polyp groups. Decreased telomere
length was noted in 92.9% (13/14) of Dukes’ C and 50% (3/6) of Dukes’ B. The dif-
ference between these two sub-groups was statistically significant. This study
suggests that the telomere length in colorectal carcinomas is decreased upon the
development of malignancy. A significant difference in telomere length between
polyps and invasive colorectal carcinomas may reflect a different biologic behav-
ior of colorectal carcinomas.
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surgically resected colon or rectum. There was a patient who
had a carcinoma and a polyp in the same specimen. These
potentially curative procedures, i.e., surgical resections for
colorectal cancer and colonoscopic or sigmoidoscopic polypec-
tomy for colorectal polyps, were performed between January
and October 2000. The embedded tissues were frozen in liq-
uid nitrogen. In the colorectal carcinoma group, there were
8 cases of Dukes’ B and 12 cases of Dukes’ C disease. Histo-
logical examinations revealed 14 cases of well differentiated
adenocarcinoma and 6 cases of moderately differentiated
adenocarcinoma. All of the samples from the colorectal polyp
group were identified as tubular adenoma, except for one
case of tubulovillous adenoma.
DNA Isolation and Southern Blot Analysis
High-molecular-weight DNA was prepared from each sam-
ple by digestion with proteinase K and extraction with phenol/
chloroform. Equivalent amounts of tumor and constitutional
DNA (10  g) were digested overnight at 37℃with 10 units/
g DNA each of RsaI/HinfI (TaKaRa, Kyoto, Japan). Thus,
the terminal restriction fragments (TRFs), containing both
the subtelomeric repetitive DNA and telomeric 5′ -TTAGGG
-3′ repeats, were liberated. The TRFs determining telomeric
length were separated by agarose (0.7%) gel electrophoresis,
denatured with 0.5 M NaOH and 1.5 M NaCl, and then
transferred by capillary transfer onto nylon membranes (Hy-
bond -N; Amersham International plc, Amersham, U.K.) for
Southern blotting. The filters were prehybridized in a hybri-
dization buffer (TeloQuant; PharMingen, San Diego, CA,
U.S.A.) for 1 hr at 65℃and then hybridized with a biotiny-
lated telomere probe (TTAGGG)4 (TeloQuant) in hybridiza-
tion buffer overnight at 65℃. The filters were washed twice
in 2×sodium saline citrate (SSC)/0.1% sodium dodecyl sul-
fate (SDS) for 5 min at room temperature and then washed
twice in 0.2×SSC/0.1% SDS for 15 min at 42℃. The filters
were blocked for 1 hr at room temperature using blocking
buffer (TeloQuant) and shaken for 1 hr at room temperature
in a streptavidin-horseradish peroxidase (<25 ng/mL) mixture
that had been diluted in the blocking buffer. The filters were
washed four times in 0.1% Tween-20 (Boehringer Mannheim
GmbH, Mannheim, Germany) in PBS for 10 min. After
mixing with equal volumes of stable peroxide and luminol/
enhancer (TeloQuant), the hybridized probe was shaken for
5 min and chemiluminescence was detected according to the
manufacturer’s instructions (TeloQuant). The filters were
exposed on radiography film (T-MAT; Kodak, U.S.A.) for
30-60sec.
Densitometry and Mean Telomere Length Measure-
ments
The telomeric lengths were quantified by densitometric
analysis of autoradiographs using a transmitter scanning
videodensitometer (Zenith Video Densitometer; Biomed,
Fullerton, CA, U.S.A.). The mean telomere length in each
sample was then identified as the peak intensity of the telom-
ere length (in kb) by densitometry. We suspected telomere
length change as shortened when the mean TRF length was
below 80% of that of the normal mucosa and lengthened
when it was above 120% of normal mucosa.
Statistical Analysis
The  2 test (SPSS 10.0) was used for the telomere length
comparisons between groups.
RESULTS
Mean telomere length in colorectal carcinomas and
polyps
The mean telomere length in the colorectal carcinoma group
(n=20; 7.12±0.14 kb) was significantly shorter than that
of the normal colonic mucosa (n=20; 9.25±0.16 kb). The
mean telomere length in colonic polyps (n=20; 9.41±0.53
kb) was slightly longer than that of the normal mucosa. 
Telomere shortening in colorectal carcinomas and
polyps
Colorectal carcinomas showed shortened (16/20; 80%),
elongated (2/20; 10%), and unchanged (2/20; 10%) mean
telomere lengths (Fig. 1). In the colonic polyp group, 4/20
(20%) showed a telomere shortening, 6/20 showed elongation,
and the remainder (10/20) showed no changes in telomere
length (Fig. 2). The frequency of telomere shortening was
significantly different between the colorectal carcinoma and
polyp groups (p<0.05)(Table 1). Among those polyps, which
Fig. 1. Terminal restriction fragment (TRF) analysis of colorectal
carcinomas. All tumor tissues, except one (Case 5), show a
decrease in the mean TRF length. N: constitutional DNA of nor-
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were identified by histopathologic findings, showed 14 tubu-
lar adenomas with mild dysplsia, 5 tubular adenomas with
moderately dysplasia and one tubulovillous adenoma with
mild dysplasia. Among 14 tubular adenomas with mild dys-
plasia, telomere shortening was showed in 3 cases (21.4%)
and that of tubular adenoma with moderately dysplasia showed
1 case (20%). The tubulovillous adenoma showed unchanged
telomere length. There was no significant difference among
histopathologic classification of polyps (Table 2). One case,
containing both a carcinoma and a polyp, showed a telomere
shortening in the carcinoma and telomere elongation in the
polyp (Fig. 3).
Relationship between telomere length shortening and
clinical factors in colorectal carcinoma
Several variables, such as age, sex, tumor location, histology,
tumor size, gross findings with Borrmann classification, and
tumor stage with lymph node metastasis, were examined for
potential links with telomere shortening in the colorectal
carcinoma group. Age and sex were not significantly associat-
ed with telomere shortening in colorectal carcinoma (Table
3). Tumor location, tumor histology, tumor size, and gross
findings with Borrmann classification were not significantly
linked with telomere shortening. Indeed, the only factor that
correlated with telomere shortening in a statistically signifi-
cant manner in colorectal carcinoma was tumor stage with
lymph node metastasis (Table 4). A decreased telomere length
was noted in 92.9% (13/14) of Dukes’ C and 50% (3/6) of
Dukes’ B. The difference between these two sub-groups was
statistically significant (p<0.05).
DISCUSSION
Telomeres, the nucleoprotein complexes at the ends of
eukaryotic chromosomes, consist of tandem arrays of 5′ -
TTAGGG-3′ repeats associated with specific proteins that
stabilize the chromosome ends and protect against enzymatic
end-degradation (1, 13, 14). Telomere length is maintained
by balancing processes that lengthen and shorten telomeres
(15). Since the telomeric loss is due to an end-replication
defect during progressive cell divisions, telomere shortening
is regarded as a molecular clock that counts the number of
cell divisions and determines the onset of cellular senescence
(5, 16, 17). Thus, the telomere length is an indicator of replica-
tive history and may also determine the replicative potential
of cells (5, 17, 18). In normal somatic cells, telomere progresses
at a rate of 50-100 bp per cell division and eventually leads
to growth arrest. Critically shortened telomeres, when cells
Fig. 2. Terminal restriction fragment (TRF) analysis of colonic
polyps. Cases 1 and 2 show a decreased telomere length, Case
3 shows no change and remaining cases show an increase in
the mean TRF length. N: normal mucosa; P: polyp.
12 34 5
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Fig. 3. Terminal restriction fragment (TRF) analysis of a patient
with both carcinoma and a polyp in the same specimen. The
mean TRF length is decreased in the tumor tissue and increased
in the polyp. N: normal mucosa; T: tumor; P: polyp.
NT NP
Tubular adenoma with mild dysplasia 14 3/5/6 21.4
Tubular adenoma with moderately dysplasia 5 1/2/2 20 p>0.05
Tubulovillous adenoma with mild dysplasia 1 0/0/1 0
No. Histolopatholgic classification






Carcinoma 20 16/2/2 80
p=0.001
Polyp 20 4/6/10 20
Lesions          No.
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are no longer able to protect the ends of chromosomes, cause
chromosome fusion and massive genomic instability that may
contribute to age-related clonal disorders (19-21).
In malignant cells, measurements of telomere length have
been used as markers of cell proliferation and population dou-
bling (1, 4, 8-10, 17, 22-27). Since the acquisition of mean
TRF values alone may be inaccurate, the mean and peak values
were analyzed in this study. Both values were lower in the
majority of the colorectal carcinomas when compared to the
normal adjacent tissues. Similarly, adenoma telomeres have
previously been reported to be shorter than those in adjacent
mucosal tissues (9). In contrast, we found that telomere lengths
in polyps varied, i.e., they were shorter than, or similar in
length to the telomeres in normal colonic tissues. 
Telomerase activity did not correlate significantly with
telomere length in colorectal carcinomas (28). This finding
suggests a mechanism for telomere maintenance whereby
telomerase potency is balanced with the speed of telomere
shortening. It is also worth noting that factors other than
telomerase might participate in maintaining the telomere
length (28). Interestingly, the telomere length in primitive
hematopoietic stem cells decreases despite telomerase activity
(29). However, it has been reported that some human tumors
and some tumor-derived cell lines display telomere elongation
in the apparent absence of telomerase activity (27, 30). Fur-
thermore, we did not investigate these factors in our study,
alternative mechanisms for telomere elongation that are inde-
pendent of human telomerase RNA have been demonstrated
in telomerase-negative, immortal human cells (31). Recently,
protein factors, such as TRF 1, TRF 2, and Pin 2 that bind
to repeat DNA sequences in telomeres, have been discovered
(32-34). These proteins are thought to affect telomere length
in human cell lines in vitro by a mechanism that remains to
be elucidated. 
In most previous studies, telomere shortening was observed
in colorectal carcinomas, although there were variations in
the extent of shortening. In addition, some colorectal carci-
nomas possessed longer telomeres than corresponding normal
colonic tissues. Because of these inconsistencies, it was impor-
tant to clarify the significance of telomere length in human
colorectal carcinomas. Therefore, we hypothesized that the
telomere length might reflect the current biological features
of individual tumors that had been imprinted during carcino-
genesis and tumor development. Shimoda et al. classified
colorectal carcinomas into 2 types according to their growth
patterns: polypoid and nonpolypoid growth carcinomas (35).
According to this classification, nonulcerating polypoid car-
cinomas are regarded as polypoid growth carcinomas that arose
from adenoma. We anticipated that colorectal carcinomas
derived from adenomas might have shorter telomeres. Takagi
et al. showed that telomere shortening in colorectal carcinomas
occurred more frequently in nonulcerating polypoid carcino-
mas than in ulcerating carcinomas (28). They also reported
that the frequency of telomere shortening was higher in as-
cending colon carcinomas than in sigmoid colon and rectal
carcinomas. In our study, there were no significant differences
in gross tumor patterns and tumor locations. There is consid-
erable evidence to indicate that proximal and distal colon
carcinomas may have different molecular characteristics, such
as DNA content, karyotype, oncogene expression, allelic dele-
tions, DNA replication errors (RER), loss of heterozygosity
(LOH), and microsatellite instability (MSI) (36-43). We did
not investigate these factors in our study. Takagi et al. also
reported that tumor histology, clinical stage, and the presence
of metastasis in colorectal carcinomas did not correlate with
the differences in telomere length. In our study, Dukes’ stage
with lymph node metastasis was a significant factor in deter-
mining the telomere length in colorectal carcinomas. Engel-
Sex NS*
Male 12 10 1 1
Female 8 6 1 1
Age (yr) NS
40-49 1 1 0 0
50-59 5 5 0 0
60-69 8 7 1 0
70-79 6 3 1 2\
*not significant
No. 
Shortened  Elongated  Unchanged  
Significance
telomere   telomere   telomere
Table 3. Correlation between telomere length and clinical
variables in colorectal cancer
Tumor location NS
Ascending colon 3 2 0 1
Transverse colon 2 1 1 0
Descending colon 3 2 1 0
Sigmoid colon 5 5 0 0
Rectum 7 6 0 1
Tumor histology NS
Well differentiated 14 12 2 0
Moderately 6 4 0 2
differentiated
Tumor size NS*
< 3.0 cm 6 3 2 1
3.1 - 4.9 cm 5 4 0 1
> 5.0 cm 9 9 0 0
Borrmann type NS
I3 3 0 0
II 11 9 1 1
III 6 4 1 1
IV 0 0 0 0
Stage p<0.05
B6 3 1 2
C1 4 1 3 1 0
No. 
Shortened  Elongated  Unchanged  
Significance
telomere   telomere   telomere
Table 4. Correlation between telomere length and clinical vari-
ables in colorectal cancer
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hardt et al. reported that telomeres were longer in tumors
with late-stage colorectal carcinoma, than in early-stage tumors
(44). These discrepancies might be due to racial differences
in the subject populations or the small number of cases studied.
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